Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 323

1.

Exacerbation of diabetic cardiac hypertrophy in OVE26 mice by angiotensin II is associated with JNK/c-Jun/miR-221-mediated autophagy inhibition.

Qian LB, Jiang SZ, Tang XQ, Zhang J, Liang YQ, Yu HT, Chen J, Xu Z, Liu RM, Keller BB, Ji HL, Cai L.

Oncotarget. 2017 Sep 28;8(63):106661-106671. doi: 10.18632/oncotarget.21302. eCollection 2017 Dec 5.

2.

Effect of prehypertensive losartan therapy on AT1R and ATRAP methylation of adipose tissue in the later life of high‑fat‑fed spontaneously hypertensive rats.

Wang T, Lian G, Cai X, Lin Z, Xie L.

Mol Med Rep. 2018 Jan;17(1):1753-1761. doi: 10.3892/mmr.2017.8081. Epub 2017 Nov 15.

3.

Does contrast media volume affect long-term survival in patients with chronic kidney disease?

Biyik I, Uzun F, Erturk M, Ozturk D, Kalkan AK, Akbay E, Akture G, Emet M, Yalcin AA, Akturk IF.

Arch Med Sci Atheroscler Dis. 2017 Nov 9;2:e82-e89. doi: 10.5114/amsad.2017.71280. eCollection 2017.

4.

Control of Hypertension among Diabetic Patients in a Referral Hospital in Tanzania: A Cross-Sectional Study.

Kilonzo SB, Gunda DW, Bakshi FA, Kalokola F, Mayala HA, Dadi H.

Ethiop J Health Sci. 2017 Sep;27(5):473-480.

5.

Trends in cardiovascular risk factors among U.S. men and women with and without diabetes, 1988-2014.

Sun X, Du T.

BMC Public Health. 2017 Nov 22;17(1):893. doi: 10.1186/s12889-017-4921-4.

7.

Is cardiovascular risk reduction therapy effective in South Asian, Chinese and other patients with diabetes? A population-based cohort study from Canada.

Ke CH, Morgan S, Smolina K, Gasevic D, Qian H, Khan NA.

BMJ Open. 2017 Aug 31;7(8):e013808. doi: 10.1136/bmjopen-2016-013808.

8.

Enhanced hemodynamic responses to angiotensin II in diabetes are associated with increased expression and activity of AT1 receptors in the afferent arteriole.

Zhang J, Qu HY, Song J, Wei J, Jiang S, Wang L, Wang L, Buggs J, Liu R.

Physiol Genomics. 2017 Oct 1;49(10):531-540. doi: 10.1152/physiolgenomics.00025.2017. Epub 2017 Aug 25.

PMID:
28842434
9.

Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS).

Perreault L, Pan Q, Aroda VR, Barrett-Connor E, Dabelea D, Dagogo-Jack S, Hamman RF, Kahn SE, Mather KJ, Knowler WC; Diabetes Prevention Program Research Group.

Diabet Med. 2017 Dec;34(12):1747-1755. doi: 10.1111/dme.13453. Epub 2017 Sep 19.

PMID:
28833481
10.

Primary Prevention of Cardiovascular Disease in Diabetes Mellitus.

Newman JD, Schwartzbard AZ, Weintraub HS, Goldberg IJ, Berger JS.

J Am Coll Cardiol. 2017 Aug 15;70(7):883-893. doi: 10.1016/j.jacc.2017.07.001. Review.

PMID:
28797359
11.

Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SBEM).

Bertoluci MC, Moreira RO, Faludi A, Izar MC, Schaan BD, Valerio CM, Bertolami MC, Chacra AP, Malachias MVB, Vencio S, Saraiva JFK, Betti R, Turatti L, Fonseca FAH, Bianco HT, Sulzbach M, Bertolami A, Salles JEN, Hohl A, Trujilho F, Lima EG, Miname MH, Zanella MT, Lamounier R, Sá JR, Amodeo C, Pires AC, Santos RD.

Diabetol Metab Syndr. 2017 Jul 14;9:53. doi: 10.1186/s13098-017-0251-z. eCollection 2017. Review.

12.

The effect of magnesium supplementation on blood pressure in individuals with insulin resistance, prediabetes, or noncommunicable chronic diseases: a meta-analysis of randomized controlled trials.

Dibaba DT, Xun P, Song Y, Rosanoff A, Shechter M, He K.

Am J Clin Nutr. 2017 Sep;106(3):921-929. doi: 10.3945/ajcn.117.155291. Epub 2017 Jul 19.

PMID:
28724644
13.

Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease.

Elajami TK, Alfaddagh A, Lakshminarayan D, Soliman M, Chandnani M, Welty FK.

J Am Heart Assoc. 2017 Jul 14;6(7). pii: e004740. doi: 10.1161/JAHA.116.004740.

15.

Genetic and epigenetic modifications in the pathogenesis of diabetic retinopathy: a molecular link to regulate gene expression.

Pradhan P, Upadhyay N, Tiwari A, Singh LP.

New Front Ophthalmol. 2016;2(5):192-204. doi: 10.15761/NFO.1000145. Epub 2016 Oct 24.

16.

Differential cardiovascular profiles of sodium-glucose cotransporter 2 inhibitors: critical evaluation of empagliflozin.

Sanon VP, Patel S, Sanon S, Rodriguez R, Pham SV, Chilton R.

Ther Clin Risk Manag. 2017 May 3;13:603-611. doi: 10.2147/TCRM.S97619. eCollection 2017. Review.

17.

Strategies and cost-effectiveness evaluation of persistent albuminuria screening among high-risk population of chronic kidney disease.

Wang H, Yang L, Wang F, Zhang L.

BMC Nephrol. 2017 Apr 18;18(1):135. doi: 10.1186/s12882-017-0538-1.

18.

Advances in understanding the renin-angiotensin-aldosterone system (RAAS) in blood pressure control and recent pivotal trials of RAAS blockade in heart failure and diabetic nephropathy.

Ghazi L, Drawz P.

F1000Res. 2017 Mar 21;6. pii: F1000 Faculty Rev-297. doi: 10.12688/f1000research.9692.1. eCollection 2017. Review.

19.

The use of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes & chronic kidney disease.

Bittle PA.

Nurse Pract. 2017 Jun 16;42(6):31-38. doi: 10.1097/01.NPR.0000512253.40369.ab. Erratum in: Nurse Pract. 2018 Feb 16;43(2):10.

20.

Vascular legacy: HOPE ADVANCEs to EMPA-REG and LEADER: A Surprising similarity.

Kalra S, Sahay R.

Indian J Endocrinol Metab. 2017 Jan-Feb;21(1):245-248. doi: 10.4103/2230-8210.194341.

Supplemental Content

Support Center